viewFrontier IP Group PLC

Frontier IP's Amprologix secures contract to take its antibiotic into the clinic

Frontier IP Group Plc’s (LON:FIPP) CEO Neil Crabb tells Proactive London's Andrew Scott its portfolio firm, Amprologix, has won a £1.2mln UK government contract to accelerate the development of a new antibiotic to tackle antimicrobial resistant MRSA and other superbugs.

As part of a broader catch up on portfolio developments since the New Year, Crabb discusses The Vaccine Group landing a £403,000 government grant. The cash received is part of a £1.46mln Anglo-Chinese project to combat an emerging antibiotic-resistant disease able to jump from pigs to humans with potentially fatal effect.

Plus he updates on Nandi Proteins which has won a grant to improve the quality of gluten-free bread.

Quick facts: Frontier IP Group PLC

Price: 67 GBX

Market: AIM
Market Cap: £33.96 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...



Frontier IP Group 'well positioned for another positive performance'

Frontier IP Group PLC's (LON:FIPP) Neil Crabb tells Proactive London's Andrew Scott he's confident their portfolio will continue to grow after profits in its latest full-year increased 160%. The fair value of the group’s investment portfolio also increased by 47% to £13.25mln, while it ended...

on 8/11/19

2 min read